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Abstract
Aim: To assess whether the effects of sodium-glucose co-transporter-2 (SGLT2)
inhibitors on cardiovascular, kidney and mortality outcomes are consistent with and
without concomitant metformin use.
Material and methods: We conducted a meta-analysis of event-driven, randomized,
placebo-controlled SGLT2 inhibitor trials that reported cardiovascular, kidney or mor-
tality outcomes by baseline metformin use. Treatment effects, reported as hazards
ratios (HRs) and 95% confidence intervals (CIs), were pooled using random-effects
meta-analysis. The main outcomes in this analysis were (i) major adverse cardiovascu-
lar events (MACE) and (ii) hospitalization for heart failure (HHF) or cardiovascular
death.
Results: We included six trials of four SGLT2 inhibitors that enrolled a total of
51 743 participants. Baseline metformin use varied from 21% in DAPA-HF to 82% in
DECLARE-TIMI 58. SGLT2 inhibitors reduced the risk of MACE, with and without
concomitant metformin use (HR 0.93, 95% CI 0.87–1.00 and HR 0.82, 95% CI
0.71–0.86, respectively; P-heterogeneity = 0.14). There were also clear and separate
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reductions in HHF or cardiovascular death with SGLT2 inhibitors, irrespective of met-
formin use (HR 0.79, 95% CI 0.73–0.86 and HR 0.74, 95% CI 0.63–0.87, respectively;
P-heterogeneity = 0.48), as well as for major kidney outcomes and all-cause mortality
(all P-heterogeneity > 0.40).
Conclusion: Treatment with SGLT2 inhibitors results in clear and consistent reduc-
tions in cardiovascular, kidney and mortality outcomes regardless of whether patients
are receiving or not receiving metformin.
K E YWORD S
cardiovascular disease, clinical trial, diabetic nephropathy, heart failure, meta-analysis, SGLT2
inhibitor
1 | INTRODUCTION
Almost all clinical practice guidelines recommend metformin as first-
line pharmacotherapy for people with type 2 diabetes mellitus
(T2DM). In light of clear evidence of benefit for cardiovascular and
kidney outcomes in large-scale randomized trials of sodium-glucose
co-transporter-2 (SGLT2) inhibitors,1,2 these agents are now rec-
ommended as the preferred second-line therapy in people who do not
achieve sufficient glucose control on metformin alone, particularly for
those with heart failure or chronic kidney disease.3
The central role of metformin in clinical practice recommenda-
tions is based largely on its tolerability, effects on body weight and
low cost, as well as the beneficial effects on myocardial infarction and
mortality outcomes demonstrated in the UK Prospective Diabetes
Study (UKPDS).4 However, that study was conducted over two
decades ago, prior to the widespread use of renin-angiotensin system
blockade, statins, and other cardioprotective therapies, therefore,
direct comparisons with treatment effects observed in contemporary
cardiovascular outcome trials of newer glucose-lowering agents are
challenging. Nevertheless, meta-analyses of randomized trials have
not demonstrated clear benefits with metformin for cardiovascular
outcomes in people with T2DM, with very limited data on effects on
kidney outcomes.5–7 In the context of robust evidence of benefit with
SGLT2 inhibitors (and glucagon-like-peptide-1 receptor agonists),
there have been some calls for a reappraisal of the role of metformin
as the first-line oral pharmacotherapy for all patients with T2DM.8
New guidelines from the European Society of Cardiology, devel-
oped in collaboration with the European Association for the Study of
Diabetes, suggest that SGLT2 inhibitors be used in patients with
T2DM who are at high or very high cardiovascular risk, irrespective of
whether they are treatment-naïve or already receiving metformin.9
Whether the effects of SGLT2 inhibitors on cardiovascular, kidney
and mortality outcomes are consistent when used with versus without
metformin is uncertain.
We therefore conducted a meta-analysis of the effects of
SGLT2 inhibitors on cardiovascular, kidney and mortality outcomes
by baseline metformin use, hypothesizing that the benefits of
treatment for clinical outcomes would be similar regardless of
metformin use.
2 | METHODS
This meta-analysis included event-driven, randomized, placebo-
controlled SGLT2 inhibitor cardiovascular or kidney outcome trials
that reported at least one cardiovascular, kidney or mortality outcome
by baseline metformin use. Treatment effects by baseline metformin
use were obtained from published reports.10–13 For eligible trials of
SGLT2 inhibitors that recruited participants with and without T2DM,
we included data only from participants with T2DM. Data from the
CANVAS Program14 and the CREDENCE trial15 were analysed by the
authors, who had full access to individual participant data for these
trials.
The main outcomes for this analysis were major adverse cardio-
vascular events (MACE), defined as cardiovascular death, non-fatal
myocardial infarction, or non-fatal stroke, and hospitalization for heart
failure (HHF) or cardiovascular death. We also assessed effects on the
following outcomes by baseline metformin use: cardiovascular death;
HHF; worsening kidney function, end-stage kidney disease or kidney
death (as defined in the published trials); and all-cause mortality.
We pooled treatment effect estimates, expressed as hazards
ratios (HRs) and 95% confidence intervals (CIs), by baseline metformin
use from each individual study using random-effects meta-analysis.
Potential heterogeneity in treatment effect estimates across baseline
metformin use was assessed using the I2 and P-heterogeneity
statistics.
To assess the impact of differences in characteristics between
participants receiving and not receiving metformin, we performed
additional analyses of the CANVAS Program and CREDENCE trial for
which we had access to individual participant data to compare
unadjusted and adjusted treatment effects. We adjusted treatment
effects estimates obtained from Cox models for baseline age, sex,
race, glycated haemoglobin, diabetes duration, history of cardiovascu-
lar disease, microvascular complications, heart failure, systolic blood
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pressure, body mass index, estimated glomerular filtration rate (eGFR),
urinary albumin: creatinine ratio, total cholesterol, triglycerides, and
insulin use. This approach was similar to that used in a subgroup anal-
ysis from the DECLARE-TIMI 58 trial.11 In these analyses, interaction
P values were obtained using likelihood ratio tests comparing models
with and without treatment by subgroup interaction terms, with no
adjustment for multiplicity.
All analyses were performed using STATA version 15.1 and SAS ver-
sion 9.4.
3 | RESULTS
We included six event-driven, randomized, placebo-controlled trials of
four SGLT2 inhibitors enrolling 51 743 participants, with median
follow-up of between 1.5 and 4.2 years. The characteristics of
included studies are summarized in Table 1. Four trials were cardio-
vascular outcome trials conducted in people with T2DM at high car-
diovascular risk: EMPA-REG OUTCOME (n = 7020), the CANVAS
program (n = 10142), DECLARE-TIMI 58 (17160), and VERTIS-CV
(8246);10,11,14,16 one (CREDENCE, n = 4401) was a kidney outcome
trial in people with T2DM and chronic kidney disease15 and one was a
heart failure trial in people with heart failure with reduced ejection
fraction, irrespective of diabetes status (DAPA-HF, n = 4744).12
The proportion of participants receiving metformin varied across
the trials. Because approximately half of the participants in DAPA-HF
did not have diabetes, this trial had the lowest proportion of partici-
pants receiving metformin at baseline (21%). CREDENCE included
fewer participants on metformin at baseline (58%) compared to other
trials that enrolled people with T2DM, in view of the much higher pro-
portion of participants with reduced kidney function. In the cardiovas-
cular outcome trials for empagliflozin, canagliflozin, dapagliflozin and
ertugliflozin, baseline use of metformin was high in each trial and
overall (74%–82%). Participants in these trials who were not receiving
metformin at baseline were more likely to be older and using insulin,
and to have a longer diabetes duration, lower eGFR and a history of
heart failure. Detailed baseline characteristics of participants by met-
formin use in the CANVAS Program and CREDENCE trial are shown
in Tables S1 and S2.
Sodium-glucose co-transporter-2 inhibitors reduced the risk of
MACE regardless of baseline metformin use (HR 0.93, 95% CI
0.87–1.00 and HR 0.82, 95% CI 0.71–0.96, respectively; P-heteroge-
neity = 0.14 [Figure 1]). For the outcome of HHF or cardiovascular
death, there were clear and separately statistically significant relative
risk reductions in people receiving and not receiving metformin at
baseline (HR 0.79, 95% CI 0.73–0.86 and HR 0.74, 95% CI 0.63–0.87;
P-heterogeneity = 0.48; [Figure 1]). For HHF alone and for cardiovas-
cular death, separately significant reductions were also observed,
irrespective of metformin use at baseline (P-heterogeneity = 0.42 and
0.43; Figures 2 and 3).
Sodium-glucose co-transporter-2 inhibitors reduced the risk of
worsening kidney function, end-stage kidney disease or kidney death
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(HR 0.58, 95% CI 0.48–0.69 and HR 0.63, 95% CI 0.48–0.83; P-het-
erogeneity = 0.62 [Figure 4]). The risk of all-cause mortality was also
lower in people treated with SGLT2 inhibitors, with consistent benefit
regardless of baseline metformin use (P-heterogeneity = 0.57;
Figure 4).
In exploratory analyses using individual participant data from the
CANVAS Program and CREDENCE trial, the effects of SGLT2 inhibi-
tion on cardiovascular, kidney and mortality outcomes by baseline
metformin use were similar after adjusting for differences between
participants receiving and not receiving metformin (Table S3 and S4).
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F IGURE 1 Effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on major adverse cardiovascular events (MACE) and hospitalization
for heart failure (HHF) or cardiovascular death by baseline metformin use. MACE were defined as nonfatal myocardial infarction, non-fatal stroke
or cardiovascular death. In DAPA-HF, HHF was defined as hospitalization or urgent visit requiring intravenous therapy for heart failure. N/A, not
available; CI, confidence interval
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4 | DISCUSSION
In this meta-analysis of the effect of SGLT2 inhibitors on cardiovascu-
lar, kidney and mortality outcomes, we observed consistent and
separately statistically significant relative risk reductions for all out-
comes, including all-cause death, irrespective of metformin use at
baseline. These data were derived from large, event-driven, random-
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F IGURE 2 Effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on hospitalization for heart failure by baseline metformin use. N/A,
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F IGURE 3 Effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on cardiovascular death by baseline metformin use. CI, confidence
interval; NA, not available
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diverse populations including participants with T2DM and established
atherosclerotic cardiovascular disease,14,16–18 T2DM and chronic kid-
ney disease,15 as well as heart failure with reduced ejection fraction,
irrespective of the presence of diabetes.19
For decades, metformin has been recommended as the first-line
pharmacological treatment for T2DM based on its tolerability, weight
benefits and low cost. The main randomized evidence supporting the
effect of metformin on patient-level outcomes comes from the
UKPDS, which demonstrated that metformin reduces the risk of
diabetes-related complications, myocardial infarction and all-cause
mortality compared to other early glucose-lowering therapies and
diet alone, both after a decade of randomized treatment and in long-
term post-trial follow-up.4,20 The UKPDS was conducted over two
decades ago, prior to the widespread use of renin-angiotensin system
blockade, statins and other widely used cardioprotective therapies,
with substantially fewer events observed in comparison to contempo-
rary cardiovascular outcome trials of glucose-lowering agents that
have been mandated by regulatory agencies.8 While the benefits of
metformin on cardiovascular outcomes have largely not been corrobo-
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F IGURE 4 Effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on (A) worsening kidney function,* end-stage kidney disease or
kidney death and (B) all-cause mortality by baseline metformin use. *Worsening kidney function was defined as doubling of serum creatinine or
progression to macroalbuminuria in EMPA-REG OUTCOME, sustained 40% decline in eGFR in the CANVAS Program and DECLARE-TIMI 58, and
sustained doubling of serum creatinine in CREDENCE. CI, confidence interval; ESKD, end-stage kidney disease
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guidelines continue to recommend that metformin be used as first-
line pharmacotherapy for people with T2DM.21 In light of evidence of
the clinical benefits of SGLT2 inhibitors, these guidelines now recom-
mend these agents as the preferred second-line therapy in people
with concomitant chronic kidney disease or heart failure who do not
achieve adequate glucose control on metformin alone.3
The results of this meta-analysis support new recommendations
from the European Society of Cardiology that suggest SGLT2 inhibi-
tors be used in patients with T2DM at high or very high cardiovascular
risk, irrespective of whether they are treatment-naïve or already
receiving metformin.22 The results of DAPA-HF, EMPEROR-Reduced
and DAPA-CKD, which demonstrated clear treatment benefits on car-
diovascular, kidney and mortality outcomes regardless of the presence
of diabetes,19,23–25 further indicate that these agents should be con-
sidered primarily as cardiovascular and kidney protective therapies,
rather than glucose-lowering agents. Taken together, the data call into
question current clinical practice recommendations that recommend
SGLT2 inhibitors be used as second-line treatment only in people who
do not achieve satisfactory glucose control with metformin alone.
There are several important factors that need to be considered
when interpreting these results. Because the T2DM cardiovascular
outcome trials recruited participants largely at high cardiovascular risk,
almost all of these individuals had a long duration of diabetes (mean
duration of greater than a decade). As a result, the data do not directly
address the question of whether SGLT2 inhibitors should be used
preferentially in patients with early T2DM, which requires a dedicated
randomized trial. An ongoing registry-based randomized trial
(SMARTEST, NCT03982381) aims to assess directly the effect of
dapagliflozin versus metformin on a primary composite endpoint of
macro- or microvascular events in approximately 4300 participants
with early T2DM, which may provide additional evidence in due
course. We had limited capacity to explore the impact of differences
between metformin and non-metformin users on treatment effects in
this meta-analysis because we used study-level data. In the CANVAS
and CREDENCE trials, where individual participant data were avail-
able, adjustment for differences in baseline characteristics did not
substantially affect the observed treatment effects. However, it is
important to recognize that it is not possible to fully account for dif-
ferences between patients receiving and not receiving metformin and
it is likely that residual confounding remains. Nevertheless, our results
were consistent with a similar analysis from the DECLARE-TIMI
58 trial.11 While we are unable to determine why specific individuals
with T2DM were not receiving metformin, the available data suggest
that most people not receiving metformin were those with longer dis-
ease duration and therefore greater need for insulin, as well as being
strongly influenced by baseline kidney function. Other factors, such as
gastrointestinal intolerance, could have also contributed. Finally, data
on kidney outcomes, which were variably defined, were not available
across all the trials. However, the consistency of the effect across the
available studies suggests that inclusion of additional data yet to be
reported is unlikely to materially alter our findings.
In conclusion, treatment with SGLT2 inhibitors results in clear
and consistent reductions in cardiovascular, kidney and mortality
outcomes regardless of whether patients are receiving or not receiv-
ing metformin.
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